课题基金 / 基金详情

项目摘要

项目成果

Matthias G. Von Herrath的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):我们的目标是从机制上了解IP-10(10 kDa干扰素诱导蛋白,CXCL 10)及其受体CXCR 3在1型糖尿病(T1 D)和胰岛移植排斥反应发病机制中的作用。基于这一认识,我们希望分析IP-10阻断在诱导和自发性自身免疫性糖尿病(RIP-LCMV和NOD小鼠)和胰岛移植的实验模型中的治疗潜力。我们相信,这种集中的分析将揭示新的干预途径,以防止破坏胰岛素产生β细胞和恢复对胰岛的长期耐受性。令人鼓舞的初步数据表明,在全身IP-10阻断后,RIPLCMV小鼠中病毒诱导的T1 D得到了显著改善。重要的是,这种临床有益效果是在没有任何可检测到的副作用的情况下获得的。一个有趣的观察结果是IP-10阻断似乎主要影响侵袭性T淋巴细胞迁移/吸引到胰岛中,而不是免疫应答的总体降低。因此,我们假设IP-10是一个独特的免疫学靶点,因为它的阻断将选择性地影响淋巴细胞在胰岛中的积聚。事实上,体内施用针对其他趋化因子的抗体没有类似的深刻影响。 目的1:IP-10在T1 D发病机制中的重要性-治疗性阻断和机制 分析。 目的2:IP-10在胰岛移植排斥反应中的重要性-治疗性阻断和机制分析。
英文摘要
DESCRIPTION (provided by applicant): Our goal is to mechanistically understand the role of IP-10 (interferon-induced protein of 10kDa, CXCL10) and its receptor CXCR3 in the pathogenesis of type 1 diabetes (T1D) and islet allograft rejection. Based on this insight we wish to analyze the therapeutic potential of IP-10 blockade in experimental models of induced and spontaneous autoimmune diabetes (RIP-LCMV and NOD mice) and islet transplantation. We believe that this focused analysis will unravel novel interventive avenues to prevent destruction of insulin producing beta-cells and restore long-term tolerance to islets. Encouraging preliminary data demonstrate a profound amelioration of virally induced T1D in RIPLCMV mice after systemic IP-10 blockade. Importantly, this clinically beneficial effect was obtained without any detectable side effects. An intriguing observation is that IP-10 blockade appears to predominantly affect migration/attraction of aggressive T lymphocytes into the islets rather than overall reduction of immune responsiveness. Thus, we hypothesize that IP-10 is a unique immunological target in that its blockade will selectively affect lymphocyte accumulation in the islets of Langerhans. Indeed, in vivo administration of antibodies against other chemokines did not have a similarly profound effect. Aim 1: Importance of IP-10 in the pathogenesis of T1D - therapeutic blockade and mechanistic analyses. Aim 2: Importance of IP-10 during islet allograft rejection - therapeutic blockade and mechanistic analyses.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI: 10.2337/db12-1370
发表时间: 2013-07
期刊: Diabetes
影响因子: 7.7
作者: [Coppieters KT, Amirian N, Pagni PP, Baca Jones C, Wiberg A, Lasch S, Hintermann E, Christen U, von Herrath MG]
通讯作者: von Herrath MG
Viral infection--a cure for type 1 diabetes?
病毒感染——1型糖尿病的治疗方法?
DOI: 10.2174/092986707781368397
发表时间: 2007
期刊: Current medicinal chemistry
影响因子: 4.1
作者: [Hintermann,Edith, Christen,Urs]
通讯作者: Christen,Urs
Treg stability in viral infection and autoimmunity
  • 批准号:
    8495227
  • 项目类别:
  • 资助金额:
    $43.73万
  • 财政年份:
    2013
  • 负责人:
    Matthias G. Von Herrath
  • 依托单位:
Treg stability in viral infection and autoimmunity
  • 批准号:
    8377922
  • 项目类别:
  • 资助金额:
    $46.53万
  • 财政年份:
    2012
  • 负责人:
    Matthias G. Von Herrath
  • 依托单位:
Specificity of CD8 cells in islets from type 1 diabetes patients
  • 批准号:
    8655830
  • 项目类别:
  • 资助金额:
    $40.14万
  • 财政年份:
    2011
  • 负责人:
    Matthias G. Von Herrath
  • 依托单位:
Specificity of CD8 cells in islets from type 1 diabetes patients
  • 批准号:
    8261913
  • 项目类别:
  • 资助金额:
    $40.14万
  • 财政年份:
    2011
  • 负责人:
    Matthias G. Von Herrath
  • 依托单位:
海外基金